Phase 1 clinical trial of CAR-NKT cell therapy shows promising results in neuroblastoma patients

Researchers at Baylor College of Medicine/Texas Children's Cancer Center and collaborating institutions report interim results from a first-in-human phase 1 clinical trial evaluating the safety, antitumor activity and immunological characteristics of a genetically engineered natural killer T (NKT) cell immunotherapy for neuroblastoma, a childhood tumor that most commonly arises in the adrenal gland.

Related Keywords

Cincinnati ,Ohio ,United States ,Texas ,Baylor College Of Medicine ,American ,Huimin Zhang ,Purva Rathi ,Meena Subramaniam ,Gabriela Barragan ,Thorsten Demberg ,Amyn Courtney ,Emily Henderson ,Linjie Guo ,Yanchuan Li ,Nisha Ghatwai ,Andrewc Sher ,Leonid Metelitsa ,Bambi Grilley ,Chunchao Zhang ,Chirag Sachar ,Birju Mehta ,Michaels Wood ,Briand Weiss ,Andras Heczey ,Claudia Martinez Amador ,Xin Xu ,Saching Thakkar ,Chenling Xu ,Tao Wang ,University Of North Carolina At Chapel Hill ,Alex Lemonade Stand Foundation For Childhood Cancer ,American Cancer Society ,Immunai Inc ,Athenex Inc ,Baldrick Foundation ,Baylor College ,Texas Children ,Cancer Center ,Nature Medicine ,Advanced Innate Cell Therapy ,Gene Therapy ,Danl Duncan Comprehensive Cancer Center ,Gengwen Tian ,Antonino Montalbano ,Cincinnati Children ,North Carolina ,Lemonade Stand Foundation ,Childhood Cancer ,Cell ,Clinical Trial ,Neuroblastoma ,Adrenal Gland ,Ntigen ,Dancer ,Children ,Chimeric Antigen Receptor ,Gene ,Hematology ,Hospital ,Immunotherapy ,N Vivo ,Nterleukin ,Medicine ,Olecule ,Ncology ,Ediatrics ,Proliferation ,Protein ,Eceptor ,Humor ,